S879 RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)

Autor:	Patricia Kropf, X. Thomas, P. Fenaux, J. Brandwein, Y. H. Min, J. Krauter, J. Novak, H. Kantarjian, J. Mayer, G.J. Roboz, Mohammad Azab, Hartmut Döhner, Wiesław Wiktor Jędrzejczak, Judit Demeter, K. Döhner, Y. Miyazaki, L. Gercheva-Kyuchukova, M. Gobbi, J.-P. Issa, Elizabeth A. Griffiths, T. Robak, K. Yee, S.-P. Yeh, M. Ojeda-Uribe
Rok vydání:	2019
Předmět:	Oncology Therapy naive medicine.medical_specialty Randomized controlled trial business.industry law Internal medicine medicine Myeloid leukemia Hematology Intensive chemotherapy business law.invention
Zdroj:	HemaSphere. 3:394-395
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000561796.30124.a4
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d026fb2f0a71d77b431cc3eb04ad02e6 https://doi.org/10.1097/01.hs9.0000561796.30124.a4 Zobrazit plný text záznamu Plný text